Medication info
J-Gaba CR Sustained Release Tablet 75mg (Pregabalin)

J-Gaba CR Sustained Release Tablet 75mg (Pregabalin)

Prescription medicationTablet
Ingredient · strength
Pregabalin›42mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
This medication is a white to light yellow rectangular film-coated sustained release tripe tablet.
Packaging
30 tablets/box [(6 tablets/PTP x 5)]
Approval status
Active

MFDS item code 202401341 · Approved 2024.05.29

Summary

Main use
Treatment of peripheral neuropathic pain in adults
Who uses it
Adults · Children
Adult dosage
Administer this medicine once daily after the evening meal. Swallow this medicine whole; do not split, crush, or chew it. As this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section '2. Patients with renal impairment'). Adults: This medicine may be administered at a starting dose of 1 tablet (150 mg) once daily. Based on the response and tolerability of each patient, the dose may be increased at weekly intervals up to a maximum of 600 mg per day. Discontinuation of treatment: Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over an interval of at least 1 week. 2. Patients with renal impairment This medicine (pregabalin 75mg) should be used only as the starting dose in patients with moderate renal impairment. Considering dose-dependent adverse reactions and the fact that pregabalin is primarily excreted by the kidneys, adjust the dose in patients with impaired renal function. Dose adjustment in patients with renal impairment is based on creatinine clearance (CLcr) [Table 1]. [Table 1] Dosage of this medicine based on renal function Creatinine clearance (CLcr)* (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), once daily Creatinine clearance (CLcr)* (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), once daily *Creatinine clearance (CLcr) can be estimated from serum creatinine (mg/dL) using the Cockcroft-Gault equation below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) *For women, multiply the result obtained from the above equation by 0.85. The safety and efficacy of this medicine have not been established in patients with severe renal impairment or end-stage renal disease with creatinine clearance (CLcr) less than 30 mL/min (see '2) Pharmacokinetic information' under '11. Information for healthcare professionals' in the Precautions for Use section). 3. Patients with hepatic impairment The safety and efficacy of this medicine have not been established in patients with hepatic impairment. 5. Older adults (aged 65 years and older) The safety and efficacy of this medicine have not been established in older adults aged 65 years and older.
Children's dosage
4. Pediatric and adolescent patients The safety and efficacy of this medicine have not been established in pediatric and adolescent patients under 19 years of age.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of peripheral neuropathic pain in adults

  • Peripheral neuropathic pain
View approved original text

This medicine is used to relieve peripheral neuropathic pain in adults. It helps to reduce pain arising from damage or abnormalities in peripheral nerves, thereby improving the quality of life for patients. Neuropathic pain is often accompanied by chronic and severe pain, so effective pain management is expected with this medication.

Dosage and Administration

Adult dosage

Administer this medicine once daily after the evening meal. Swallow this medicine whole; do not split, crush, or chew it. As this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section '2. Patients with renal impairment'). Adults: This medicine may be administered at a starting dose of 1 tablet (150 mg) once daily. Based on the response and tolerability of each patient, the dose may be increased at weekly intervals up to a maximum of 600 mg per day. Discontinuation of treatment: Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over an interval of at least 1 week. 2. Patients with renal impairment This medicine (pregabalin 75mg) should be used only as the starting dose in patients with moderate renal impairment. Considering dose-dependent adverse reactions and the fact that pregabalin is primarily excreted by the kidneys, adjust the dose in patients with impaired renal function. Dose adjustment in patients with renal impairment is based on creatinine clearance (CLcr) [Table 1]. [Table 1] Dosage of this medicine based on renal function Creatinine clearance (CLcr)* (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), once daily Creatinine clearance (CLcr)* (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), once daily *Creatinine clearance (CLcr) can be estimated from serum creatinine (mg/dL) using the Cockcroft-Gault equation below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) *For women, multiply the result obtained from the above equation by 0.85. The safety and efficacy of this medicine have not been established in patients with severe renal impairment or end-stage renal disease with creatinine clearance (CLcr) less than 30 mL/min (see '2) Pharmacokinetic information' under '11. Information for healthcare professionals' in the Precautions for Use section). 3. Patients with hepatic impairment The safety and efficacy of this medicine have not been established in patients with hepatic impairment. 5. Older adults (aged 65 years and older) The safety and efficacy of this medicine have not been established in older adults aged 65 years and older.

Children's dosage

4. Pediatric and adolescent patients The safety and efficacy of this medicine have not been established in pediatric and adolescent patients under 19 years of age.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so you must immediately inform healthcare personnel if you experience mood changes or symptoms of depression during treatment. Patients with an allergy to any ingredient in this medication should not take it. Diabetic patients may experience weight gain from this medication and may need to adjust the dosage of blood sugar control medications. If allergic reactions such as angioedema occur, discontinue the medication immediately and consult your healthcare provider. Elderly patients may have an increased risk of injury from dizziness or drowsiness caused by this medication, so caution is advised. Blurry vision or changes in vision may occur, and these symptoms may improve after discontinuation of the medication. Abrupt discontinuation of this medication can result in withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off gradually in consultation with healthcare personnel. Due to the risk of drug abuse, patients with a history of substance abuse should exercise particular caution when taking this medication. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should consult healthcare personnel before taking this medication. Caution is required when taking this medication in combination with opioid analgesics as it may increase the risk of central nervous system depression. There may be a serious risk of respiratory depression in patients with respiratory or neurological disorders, renal impairment, and the elderly, so dosage adjustments may be necessary. During early pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant must consult healthcare personnel before taking this medication and use effective contraception. This medication may cause dizziness and drowsiness, so caution is advised when driving or operating dangerous machinery. Severe skin reactions may occur rarely, so if any unusual symptoms like skin rash or swelling appear, discontinue the medication immediately and inform your healthcare provider. This medication has minimal pharmacokinetic interactions with other drugs; however, caution is advised when taken with alcohol or central nervous system depressants, as it may enhance effects and increase side effect risks. Women who are breastfeeding should consult healthcare personnel since this medication may be excreted in breast milk and consider whether to discontinue breastfeeding or the medication. In case of overdose, symptoms such as drowsiness, confusion, and seizures may occur, and immediate medical attention is required.

Side effects

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial edema, periorbital edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, diarrhea, influenza-like syndrome, restlessness, thoughts of suicide, pain, seizures, hyperhidrosis, weight gain, constipation, dyspepsia, nausea, dry mouth, vomiting, peripheral edema, bradycardia, palpitations, itching, arthralgia, hypoglycemia, rhinitis, hypertension, blurred vision, diplopia, vertigo, first-degree atrioventricular block, tachycardia, sinus bradycardia, hypotension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory suppression, abdominal distension, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle twitching, neck pain, muscle rigidity, rhabdomyolysis, urinary dysfunction, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, breast enlargement, gait disturbance, falls, feeling intoxicated, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, increased alanine aminotransferase, increased creatine phosphokinase in the blood, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased potassium in the blood, weight loss, increased creatinine in the blood, decreased white blood cell count, hypersensitivity, allergic reaction, keratitis, congestive heart failure, pulmonary edema, tongue swelling, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, reduced mobility, Guillain-Barré syndrome, discomfort in the head, palpitations, weakness, heat sensation, deep vein thrombosis, pneumonia, thalamic infarction, osteoarthritis, ganglion cyst, anemia, oral perceptual disturbances, bruising, diabetic retinopathy, atrial fibrillation, hyperhidrosis, thyroid nodule, spinal canal stenosis, musculoskeletal discomfort, limb discomfort, abdominal pain, upper abdominal pain, eyelid edema, cataract, increased serum alkaline phosphatase, ear disorders, Bell's palsy, dizziness, confusion, spatial disorientation, irritability, happiness, decreased libido, depersonalization, sexual arousal disorder, anxiety, mood fluctuations, decreased emotional state, elevated emotional state, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, loss of inhibition, apathy

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius to help preserve the efficacy and safety of the medication over time.

Appearance and packaging

Appearance

This medication is a white to light yellow rectangular film-coated sustained release tripe tablet.

Package unit

30 tablets/box [(6 tablets/PTP x 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.